Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CV Therapeutics gets Ranexa tradename in the EU

This article was originally published in Scrip

Executive Summary

CV Therapeutics will be able to market its novel angina treatment ranolazine as Ranexa in Europe following approval of the brand name by theEMEA. The product was granted approval last month for use as Latixa as an add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or are intolerant to first-line antianginal therapies. The Ranexa name is used in the product's first market, the US, allowing brand synergy across these two major markets, CV Therapeutics notes.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts